Stock 6976 ACEPODIA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Acepodia, Inc.

Equities

6976

KYG0073G1091

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 18:00:00 2024-05-30 EDT 		5-day change 1st Jan Change
27.75 TWD -1.42% Intraday chart for Acepodia, Inc. +0.73% -18.74%
05-08 Acepodia Announces Preliminary Clinical Data From Phase 1 Clinical Trial of ACE1831, First-Ever Anti-CD20 Antibody Conjugated Allogenic Gamma Delta T Cell Therapy for Non-Hodgkins Lymphoma CI
02-06 US FDA OKs Acepodia's Investigational New Drug Application for Cancer Treatment MT

Valuation

Fiscal Period: December 2023
Capitalization 1 19,330
Enterprise Value (EV) 1 13,310
P/E ratio -23.7 x
Yield -
Capitalization / Revenue 1,164,949,835 x
EV / Revenue 802,135,636 x
EV / EBITDA -31.4 x
EV / FCF -33,887,770 x
FCF Yield -0%
Price to Book 3.01 x
Nbr of stocks (in thousands) 566,033
Reference price 2 34.15
Announcement Date 3/25/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales - - - 16.59
EBITDA 1 -146.8 -471.5 -507 -423.7
EBIT 1 -149.6 -477.3 -517.6 -436
Operating Margin - - - -2,627.46%
Earnings before Tax (EBT) 1 -455 -878.5 -1,414 -816.5
Net income 1 -455 -878.5 -1,414 -817.3
Net margin - - - -4,925.69%
EPS 2 -10.07 -19.42 -30.79 -1.441
Free Cash Flow - - -203.4 -392.8
FCF margin - - - -2,367.04%
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 8/9/23 7/6/23 7/6/23 3/25/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 693 1,484 3,011 -
Net Cash position 1 - - - 6,020
Leverage (Debt/EBITDA) -4.724 x -3.148 x -5.94 x -
Free Cash Flow - - -203 -393
ROE (net income / shareholders' equity) - - 63.2% -47.8%
ROA (Net income/ Total Assets) - - -8.33% -5.1%
Assets 1 - - 16,983 16,034
Book Value Per Share 2 -15.70 -32.40 -64.40 11.30
Cash Flow per Share 2 4.990 34.30 79.70 11.10
Capex 1 3.62 28.7 7.71 179
Capex / Sales - - - 1,081%
Announcement Date 8/9/23 7/6/23 7/6/23 3/25/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ACEPODIA, INC. Stock Acepodia, Inc.
-18.74% 486M
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.63B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-11.83% 10.74B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 6976 Stock
  4. Financials Acepodia, Inc.